Company intelligence / Profile preview

Enalare Therapeutics

Princeton, New Jersey, United Statesenalare.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Enalare is developing ENA-001, an agnostic respiratory stimulant with a novel mechanism of action. The company has completed multiple preclinical studies and is advancing clinical trials for various indications including drug overdose respiratory depression and post-operative respiratory depression. The FDA has recently cleared the company to initiate a Phase 1 clinical study of ENA-001 for respiratory depression associated with drug overdose.

Therapeutic areas: OtherPulmonologyPsychiatryInfectious Diseases
Modalities: Small moleculesNew Chemical Entities (NCEs)
Industry: Biotech

Drug pipeline

3 assets

ENA-001

2 more assets in the full pipeline.

Request access →

Partnerships

Biomedical Advanced Research and Development Authority (BARDA)Eagle Pharmaceuticals

Beyond the preview

Go deeper on Enalare Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enalare Therapeutics.

Explore the full profile